These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

289 related items for PubMed ID: 11353655

  • 1. In vitro activities of three nonfluorinated quinolones against representative bacterial isolates.
    Barry AL, Fuchs PC, Brown SD.
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1923-7. PubMed ID: 11353655
    [Abstract] [Full Text] [Related]

  • 2. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan.
    Sheng WH, Wang JT, Chen YC, Chang SC, Luh KT.
    J Microbiol Immunol Infect; 2001 Sep; 34(3):178-84. PubMed ID: 11605808
    [Abstract] [Full Text] [Related]

  • 3. Antimicrobial activity of fluoroquinolones and other antibiotics on 1,116 clinical gram-positive and gram-negative isolates.
    Mascellino MT, Farinelli S, Iegri F, Iona E, De Simone C.
    Drugs Exp Clin Res; 1998 Sep; 24(3):139-51. PubMed ID: 9825230
    [Abstract] [Full Text] [Related]

  • 4. [In vitro evaluation of lomefloxacin].
    Dette GA, Knothe H.
    Arzneimittelforschung; 1989 Aug; 39(8):832-5. PubMed ID: 2818672
    [Abstract] [Full Text] [Related]

  • 5. In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms.
    Almer LS, Hoffrage JB, Keller EL, Flamm RK, Shortridge VD.
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2771-7. PubMed ID: 15215148
    [Abstract] [Full Text] [Related]

  • 6. Comparative antimicrobial activity of lomefloxacin, norfloxacin, ofloxacin, ciprofloxacin and enoxacin against > 500 bacterial isolates.
    Ismaeel NA, Tayeb OS.
    Microbios; 1993 Jul; 74(300):147-54. PubMed ID: 8396196
    [Abstract] [Full Text] [Related]

  • 7. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin.
    Gilbert DN, Kohlhepp SJ, Slama KA, Grunkemeier G, Lewis G, Dworkin RJ, Slaughter SE, Leggett JE.
    Antimicrob Agents Chemother; 2001 Mar; 45(3):883-92. PubMed ID: 11181375
    [Abstract] [Full Text] [Related]

  • 8. Quinolone resistance in Staphylococci: activities of new nonfluorinated quinolones against molecular targets in whole cells and clinical isolates.
    Roychoudhury S, Catrenich CE, McIntosh EJ, McKeever HD, Makin KM, Koenigs PM, Ledoussal B.
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1115-20. PubMed ID: 11257024
    [Abstract] [Full Text] [Related]

  • 9. In vitro activity of E-3846, a new fluoroquinolone, against gram-negative and gram-positive bacteria.
    Moros M, Coll R, Esteve M, Parés J, Xicota MA.
    Chemioterapia; 1987 Jun; 6(2 Suppl):149-51. PubMed ID: 3509373
    [No Abstract] [Full Text] [Related]

  • 10. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).
    Sader HS, Fritsche TR, Jones RN.
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569
    [Abstract] [Full Text] [Related]

  • 11. [In vitro antibacterial activity of lomefloxacin, a new fluoroquinolone, against hospital strains. Results of a multicenter study].
    Soussy CJ, Le Van Thoi J, Morel C, Acar JF, Thabaut A, Fleurette J, Vallée E, Dabernat H, Chanal M, Drugeon H.
    Pathol Biol (Paris); 1990 May; 38(5):390-6. PubMed ID: 2195448
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of current activities of fluoroquinolones against gram-negative bacilli using centralized in vitro testing and electronic surveillance.
    Sahm DF, Critchley IA, Kelly LJ, Karlowsky JA, Mayfield DC, Thornsberry C, Mauriz YR, Kahn J.
    Antimicrob Agents Chemother; 2001 Jan; 45(1):267-74. PubMed ID: 11120976
    [Abstract] [Full Text] [Related]

  • 13. In vitro antibacterial activities of AF 3013, the active metabolite of prulifloxacin, against nosocomial and community Italian isolates.
    Montanari MP, Mingoia M, Varaldo PE.
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3616-22. PubMed ID: 11709353
    [Abstract] [Full Text] [Related]

  • 14. Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004).
    Fritsche TR, Sader HS, Jones RN.
    Diagn Microbiol Infect Dis; 2007 May; 58(1):19-26. PubMed ID: 17383139
    [Abstract] [Full Text] [Related]

  • 15. A multicenter study on the comparative in vitro activity of fleroxacin and three other quinolones: an interim report from 27 centers.
    Beskid G, Prosser BL.
    Am J Med; 1993 Mar 22; 94(3A):2S-8S. PubMed ID: 8383919
    [Abstract] [Full Text] [Related]

  • 16. The spectrum of Gram-positive bloodstream infections in patients with hematologic malignancies, and the in vitro activity of various quinolones against Gram-positive bacteria isolated from cancer patients.
    Rolston KV, Yadegarynia D, Kontoyiannis DP, Raad II, Ho DH.
    Int J Infect Dis; 2006 May 22; 10(3):223-30. PubMed ID: 16439177
    [Abstract] [Full Text] [Related]

  • 17. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.
    Noviello S, Ianniello F, Leone S, Esposito S.
    J Antimicrob Chemother; 2003 Nov 22; 52(5):869-72. PubMed ID: 14519672
    [Abstract] [Full Text] [Related]

  • 18. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin.
    Barry AL, Fuchs PC.
    J Chemother; 1997 Feb 22; 9(1):9-16. PubMed ID: 9106012
    [Abstract] [Full Text] [Related]

  • 19. [In vitro activity of trovafloxacin, of other fluoroquinolones and of related antimicrobials against clinical isolates. Grupo colaborativo WHONET-Argentina].
    Rossi A, Galas M, Tokumoto M, Guelfand L, Lopardo H.
    Medicina (B Aires); 1999 Feb 22; 59 Suppl 1():8-16. PubMed ID: 10436549
    [Abstract] [Full Text] [Related]

  • 20. Activity of 4-quinolones against Pseudomonas aeruginosa.
    Morissey I, Smith JT.
    Arzneimittelforschung; 1994 Oct 22; 44(10):1157-61. PubMed ID: 7818593
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.